Anidulafungin: a novel echinocandin

Clin Infect Dis. 2006 Jul 15;43(2):215-22. doi: 10.1086/505204. Epub 2006 Jun 9.


Until recently, the treatment available for serious fungal infections was composed of amphotericin B and azoles, and each class demonstrated significant limitations. Echinocandins are a new class of drugs that have shown promising results in treating a variety of fungal infections. Of these, anidulafungin is a novel echinocandin that appears to have several advantages over existing antifungals. It is unique because it slowly degrades in humans, undergoing a process of biotransformation rather than being metabolized. It has potent in vitro activity against Aspergillus and Candida species, including those resistant to fluconazole or amphotericin B. Results of several clinical trials indicate that anidulafungin is effective in treating esophageal candidiasis, including azole-refractory disease. The results of a recent study comparing fluconazole versus anidulafungin demonstrated the superiority of anidulafungin in the treatment of candidemia and invasive candidiasis (IC). Studies evaluating the concomitant use of anidulafungin and either amphotericin B, voriconazole, or cyclosporine did not demonstrate significant drug-drug interactions or adverse events. To date, anidulafungin appears to have an excellent safety profile. On the basis of early clinical experience, it appears that anidulafungin will be a valuable asset in the management of serious and difficult-to-treat fungal infections.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anidulafungin
  • Antifungal Agents / pharmacokinetics
  • Antifungal Agents / pharmacology*
  • Antifungal Agents / therapeutic use*
  • Echinocandins
  • Fungal Proteins
  • Humans
  • Mycoses / drug therapy*
  • Peptides, Cyclic / pharmacokinetics
  • Peptides, Cyclic / pharmacology
  • Peptides, Cyclic / therapeutic use*


  • Antifungal Agents
  • Echinocandins
  • Fungal Proteins
  • Peptides, Cyclic
  • Anidulafungin